All stock reports

DPABHUSHAN evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • Financial data quality flags require resolution.
  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-09-06T04:32:42.202272+00:00

Metrics

latest_annual_period
2026-03-31
revenue
40651283000.0
net_income
2118404000.0
operating_cash_flow
-1133593000.0
free_cash_flow
-1217279000.0
total_assets
11426167000.0
total_liabilities
5100043000.0
total_equity
6326124000.0
cash
257546000.0
total_debt
3038259000.0
revenue_growth
0.22784231389835585
earnings_growth
0.8797591740575268
net_margin
0.05211161477978444
roe
0.33486602538932214
debt_to_equity
0.48027180624344384
cash_conversion
-0.5351165311243747
free_cash_flow_margin
-0.02994441774445348
trailing_pe
13.6863
forward_pe
0.0
peg_ratio
Not supplied
price_to_book
5.2085
dividend_yield
Not supplied

Other positional research

Research only

1 opportunity assessments; compare evidence and conditions below.

Breakout Volatility Expansion

Research only. Direction: LONG.

Tests range escape confirmed by participation expansion

  • No active, unexpired validation authority for this exact strategy and horizon.
  • A source-backed entry, invalidation, exit and cost plan is not supplied.
Eligible expression
None selected
Expression comparison
No eligible instrument selected.
Invalidation
False breakout back into range
Entry rule
Not supplied
Entry range (INR)
Not supplied
Exit / review rule
Not supplied
Planned exit
Not supplied
Plan valid until
Not supplied
Promotion reference
Not supplied
Instrument scenarios in INR; quantities are illustrative, not personal sizing
InstrumentEvidence statusContractQuantityCapital / marginTarget P&L after costsStop-level scenario P&LStress lossConditions and limitations
NO_POSITIONAvailableNot suppliedNot suppliedNot supplied0.000.00Not suppliedNo new position; incremental trading P&L is zero.
CASHUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
FUTURESUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
OPTIONSUnavailableNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedNot suppliedObserved contract, quote and cost evidence not supplied.
  • No reader capital or loss budget supplied
Decision provenance and limitations
Decision ID
decision-8cebb3a4635a24226b9f1551c4ca50c7e4d96dc2db8bec50f61c3e198ef46756
Policy
stock-decisions-v1
Evidence bundle hash
c227b7094aafd2fbeb285345748cc3f4637ae0cbee892076045d6b7511b3c272
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 40e70e955674ee0a478a936cc6a80d327b912d70b9136f2dc32961d83caebd42
  • daily-price: bbfe6f6b963600f545e722b15581ff8553de5b0ba22d776c9127444985baab92
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

Price source verification: REPAIRED. The trailing 5-session price return was 33.32%. The trailing 20-session price return was 36.75%. The trailing 60-session price return was 74.16%. The trailing 250-session price return was 25.05%. Average cached traded value over twenty sessions was INR 256,927,193.

Risks

The cached financial metric cash conversion is -0.5351165311243747. The cached financial metric free cash flow margin is -0.02994441774445348. Financial data check: weak_cash_conversion: operating cash flow/net income below 0.5.

Follow Up

The cached financial metric latest annual period is 2026-03-31. Fundamental coverage is FULL_STATEMENTS; retrieved 2026-09-06T04:32:42.202272+00:00 from EODHD.

Cached observations and evidence limits